ALGS SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 5, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 6, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 6, 2025

News

TYPE

HEADLINE

FILED AT

8-K

Aligos Therapeutics Reports Third Quarter 2026 Financial Results and Business Progress

Nov 6, 2026

8-K

Aligos Therapeutics Amends Headquarters Lease Extending Term to 2034

Sep 15, 2026

8-K

Aligos Therapeutics Reports Q2 2026 Financial Results and Pipeline Progress

Aug 6, 2026

8-K

Aligos Therapeutics, Inc. Announces Results of 2026 Annual Meeting of Stockholders

Jun 26, 2026

8-K

Aligos Therapeutics Reports Q1 2026 Financial Results and Business Progress

May 7, 2026

8-K

Aligos Therapeutics Enters Licensing Agreement with Xiamen Amoytop Biotech for Pevifoscorvir Sodium

Apr 21, 2026

Prospectus

TYPE

HEADLINE

FILED AT

424B3

UPDATED | SHARE RESALE REGISTRATION | Shares amount: 6,245,475 | Warrants amount: 4,014,200

Apr 3, 2025

424B3

UPDATED

Nov 28, 2023

424B4

OFFERING | Shares amount: 4,400,000 | Share price: $19.00 | Offering amount: $83,600,000.00

Jul 1, 2021

424B4

10,000,000 shares

Oct 19, 2020

Registrations

TYPE

HEADLINE

FILED AT

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 5, 2026

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Aug 6, 2025

S-3

SHARE RESALE REGISTRATION | Shares amount: 6,245,475 | Warrants amount: 3,930,420

Mar 27, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 10, 2025

Form D - Notice of Exempt Offering of Securities - Item 06b

Feb 28, 2025

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2026

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 29, 2026

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

PRE 14A

Form PRE 14A - Other preliminary proxy statements

Apr 16, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 29, 2024

Ownerships

TYPE

HEADLINE

FILED AT

Preston Heather (Reporting)

Jun 29, 2026

Chavez Margarita (Reporting)

Jun 29, 2026

Martell Bridget A (Reporting)

Jun 29, 2026

Scopa James Paul (Reporting)

Jun 29, 2026

Nuechterlein Carole (Reporting)

Jun 29, 2026

Hirth Peter (Reporting)

Jun 29, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

Apr 4, 2025

CORRESP

Form CORRESP - Correspondence

Apr 1, 2025

LETTER

Form UPLOAD - SEC-generated letter

Apr 1, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

Nov 19, 2024

CORRESP

Form CORRESP - Correspondence

Nov 14, 2024

LETTER

Form UPLOAD - SEC-generated letter

Nov 13, 2024

Aligos Therapeutics, Inc. ALGS · SEC Filings